Takara Bio (4974.T) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

4974.T · Stock Price

JPY 1,142+315 (+38.09%)

Market Cap: $878.5M

Historical price data

Overview

Takara Bio's mission is to contribute to the advancement of life sciences and the improvement of human health through its integrated technology platforms. The company has achieved global leadership in PCR reagents, established a top-tier viral vector CDMO, and is advancing a pipeline of in-house gene and cell therapies. Its strategy hinges on the synergistic interplay between its Bioindustry, Gene Therapy, and Cell Medicine segments, creating a unique, full-spectrum biotech enterprise that monetizes innovation from the lab bench to the clinic.

OncologyRegenerative Medicine

Technology Platform

An integrated ecosystem of proprietary platforms for PCR/NGS reagents, viral vector manufacturing (rAAVpro, Lenti-vpro), and cell processing, enabling a seamless workflow from research tools to therapeutic development and manufacturing.

Pipeline

12

12 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
TBI-1301 + Cyclophosphamide + Fludarabine	Synovial Sarcomas	Phase 3
HF10 plus Ipilimumab	Malignant Melanoma	Phase 2
Nivolumab + HF10	Melanoma	Phase 2
TBI-1401(HF10) + Ipilimumab	Melanoma Stage III	Phase 2
TBI-1501	Lymphoblastic Leukemia, Acute Adult	Phase 1/2

Funding History

1

IPOUndisclosedUndisclosedDec 21, 2004

Opportunities

Takara Bio is poised to capitalize on the explosive growth of the gene therapy CDMO market, bottlenecked by limited manufacturing capacity, and the sustained demand for advanced life science research tools.

Its integrated model allows it to monetize the cell and gene therapy revolution at multiple points: enabling research, providing manufacturing services, and developing proprietary drugs.

Risk Factors

Key risks include clinical failure of its internal therapeutic pipeline, execution challenges in scaling its high-demand CDMO capacity, technological disruption in its core reagent business, and intensifying competition from larger, well-capitalized global CDMOs and life science tools companies.

Competitive Landscape

Takara competes with life science tool giants (Thermo Fisher, Qiagen) in reagents, pure-play CDMOs (Lonza, Catalent) in viral vectors, and numerous biotechs in drug development. Its unique vertical integration, especially its proprietary rAAVpro manufacturing platform, provides a differentiated competitive moat.

More companies in Cell & Gene Therapy →More companies in Japan →